Is Amgen's Nplate a Blockbuster?

Recs

2

Disney Buys Marvel!

...And David Gardner called it. He's up 1,334%! See what David's recommending that you buy NEXT!

Click here now to find out!

The U.S. may be the largest drug market in the world, but the European Union isn't too shabby. Amgen (Nasdaq: AMGN) is headed there next with Nplate, its blood-clotting drug for idiopathic thrombocytopenic purpura (ITP) -- a disorder that involves the body destroying its own platelets.

On Friday, the Committee for Medicinal Products for Human Use (CHMP) recommended approval of the drug. Now Amgen just needs to wait until final approval by the European Medicines Agency (EMEA) before it can start negotiating with government-sponsored health plans.

Unlike in the U.S., where GlaxoSmithKline (NYSE: GSK) and Ligand Pharmaceuticals (Nasdaq: LGND) got their ITP drug Promacta approved last week, Amgen won't have to worry about competition from Promacta in the E.U. for awhile. Glaxo hasn't even submitted an application to E.U. officials yet, although it's planning on getting the packet in by the end of the year.

Amgen won't capture all of the ITP patients in Europe, estimated at 50,000. Its label is for second-line use. Patients who are stable on steroids or Genentech (NYSE: DNA) and Biogen Idec's (Nasdaq: BIIB) Rituxan aren't likely to switch. But there's still a subset of patients unable to boost their blood platelet levels who will certainly be willing to try Nplate.

Nplate isn't likely to become the next Enbrel for Amgen, given the small population it treats, but if Amgen can get it approved to treat other indications like myelodysplastic syndrome (MDS) -- another blood-cell-production problem -- it has a shot at hitting blockbuster status. Heading to Europe is a big step toward getting to that $1-billion-per-year threshold.

More Foolishness:

Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. GlaxoSmithKline is a Motley Fool Income Investor recommendation. Biogen Idec is a Stock Advisor selection. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 16, 2009, at 8:13 PM, cdulan wrote:

    Where are the numbers? This is crappy research. There is nothing in this article to even convince me to research the stock. Please do better next time.

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 781978, ~/Articles/ArticleHandler.aspx, 11/8/2009 6:30:20 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Which Companies Can Buy It Like Buffett?

Related Tickers

3/26/2009 4:00 PM
DNA $94.97 Down +0.00 +0.00%
Genentech, Inc. CAPS Rating: ****
GSK $40.52 Up +0.06 +0.15%
GlaxoSmithKline pl… CAPS Rating: *****
AMGN $54.69 Up +0.64 +1.18%
Amgen, Inc. CAPS Rating: ****
BIIB $45.76 Up +1.37 +3.09%
Biogen Idec, Inc. CAPS Rating: ****
LGND $2.00 Up +0.09 +4.71%
Ligand Pharmaceuti… CAPS Rating: ****

Community: Investing Wiki

Term Of The Hour

Buying in thirds: Buying in thirds is a time-honored Motley Fool practice, teaching investors to enter an eventual "full" stockholding in three separate lots. This is typically advisable for those who are new to investing, those who like a stock long-term but worry about its present valuation being high, and those who like to dollar-cost average.

Want to learn more or edit this definition?
Click here to read more!